Cargando…

Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets

INTRODUCTION: In observational studies with mortality endpoints, one needs to consider how to account for subjects whose interventions appear to be part of ‘end-of-life’ care. OBJECTIVE: The objective of this study was to develop a diagnostic predictive model to identify those in end-of-life care at...

Descripción completa

Detalles Bibliográficos
Autores principales: Swerdel, Joel N., Reps, Jenna M., Fife, Daniel, Ryan, Patrick B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165142/
https://www.ncbi.nlm.nih.gov/pubmed/31939079
http://dx.doi.org/10.1007/s40264-020-00906-7
_version_ 1783523417815777280
author Swerdel, Joel N.
Reps, Jenna M.
Fife, Daniel
Ryan, Patrick B.
author_facet Swerdel, Joel N.
Reps, Jenna M.
Fife, Daniel
Ryan, Patrick B.
author_sort Swerdel, Joel N.
collection PubMed
description INTRODUCTION: In observational studies with mortality endpoints, one needs to consider how to account for subjects whose interventions appear to be part of ‘end-of-life’ care. OBJECTIVE: The objective of this study was to develop a diagnostic predictive model to identify those in end-of-life care at the time of a drug exposure. METHODS: We used data from four administrative claims datasets from 2000 to 2017. The index date was the date of the first prescription for the last new drug subjects received during their observation period. The outcome of end-of-life care was determined by the presence of one or more codes indicating terminal or hospice care. Models were developed using regularized logistic regression. Internal validation was through examination of the area under the receiver operating characteristic curve (AUC) and through model calibration in a 25% subset of the data held back from model training. External validation was through examination of the AUC after applying the model learned on one dataset to the three other datasets. RESULTS: The models showed excellent performance characteristics. Internal validation resulted in AUCs ranging from 0.918 (95% confidence interval [CI] 0.905–0.930) to 0.983 (95% CI 0.978–0.987) for the four different datasets. Calibration results were also very good, with slopes near unity. External validation also produced very good to excellent performance metrics, with AUCs ranging from 0.840 (95% CI 0.834–0.846) to 0.956 (95% CI 0.952–0.960). CONCLUSION: These results show that developing diagnostic predictive models for determining subjects in end-of-life care at the time of a drug treatment is possible and may improve the validity of the risk profile for those treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40264-020-00906-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7165142
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-71651422020-04-24 Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets Swerdel, Joel N. Reps, Jenna M. Fife, Daniel Ryan, Patrick B. Drug Saf Original Research Article INTRODUCTION: In observational studies with mortality endpoints, one needs to consider how to account for subjects whose interventions appear to be part of ‘end-of-life’ care. OBJECTIVE: The objective of this study was to develop a diagnostic predictive model to identify those in end-of-life care at the time of a drug exposure. METHODS: We used data from four administrative claims datasets from 2000 to 2017. The index date was the date of the first prescription for the last new drug subjects received during their observation period. The outcome of end-of-life care was determined by the presence of one or more codes indicating terminal or hospice care. Models were developed using regularized logistic regression. Internal validation was through examination of the area under the receiver operating characteristic curve (AUC) and through model calibration in a 25% subset of the data held back from model training. External validation was through examination of the AUC after applying the model learned on one dataset to the three other datasets. RESULTS: The models showed excellent performance characteristics. Internal validation resulted in AUCs ranging from 0.918 (95% confidence interval [CI] 0.905–0.930) to 0.983 (95% CI 0.978–0.987) for the four different datasets. Calibration results were also very good, with slopes near unity. External validation also produced very good to excellent performance metrics, with AUCs ranging from 0.840 (95% CI 0.834–0.846) to 0.956 (95% CI 0.952–0.960). CONCLUSION: These results show that developing diagnostic predictive models for determining subjects in end-of-life care at the time of a drug treatment is possible and may improve the validity of the risk profile for those treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40264-020-00906-7) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-01-14 2020 /pmc/articles/PMC7165142/ /pubmed/31939079 http://dx.doi.org/10.1007/s40264-020-00906-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research Article
Swerdel, Joel N.
Reps, Jenna M.
Fife, Daniel
Ryan, Patrick B.
Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets
title Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets
title_full Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets
title_fullStr Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets
title_full_unstemmed Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets
title_short Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets
title_sort developing predictive models to determine patients in end-of-life care in administrative datasets
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165142/
https://www.ncbi.nlm.nih.gov/pubmed/31939079
http://dx.doi.org/10.1007/s40264-020-00906-7
work_keys_str_mv AT swerdeljoeln developingpredictivemodelstodeterminepatientsinendoflifecareinadministrativedatasets
AT repsjennam developingpredictivemodelstodeterminepatientsinendoflifecareinadministrativedatasets
AT fifedaniel developingpredictivemodelstodeterminepatientsinendoflifecareinadministrativedatasets
AT ryanpatrickb developingpredictivemodelstodeterminepatientsinendoflifecareinadministrativedatasets